Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist

This publication has 10 references indexed in Scilit:

• Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
  Journal of Clinical Oncology, 2000
• Do patients with advanced breast cancer benefit from chemotherapy?
  British Journal of Cancer, 1998
• Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer
  European Journal Of Cancer, 1998
• Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial
  Quality of Life Research, 1994
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
  JNCI Journal of the National Cancer Institute, 1993
• Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer
  Annals of Oncology, 1992
• Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life
  European Journal Of Cancer, 1992
• Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist
  British Journal of Cancer, 1990
• Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
  New England Journal of Medicine, 1987
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958